Palazestrant
Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research.
Product Specifications
CAS Number
2092925-89-6
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
449.6
Molecular Formula
C28H36FN3O
Notes
Research use only, not for human use.
Receptor
Estrogen/progestogen Receptor
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
M00102-2-FITC 100 µg/Vial
Anti-human IL6 Antibody (monoclonal, 7D12)-FITC Conjugate
Sign In for Pricing
View Details 
GR126123 100 µg
Genorise® Human Cytokeratin 19 (CK19) Monoclonal Antibody
Sign In for Pricing
View Details 